HHS, Defense Department invest in manufacturing demonstration to produce 100 million COVID-19 investigational vaccine doses
The Department of Health and Human Services today announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.
The investment is expected to yield 100 million fill-finished doses, meaning vaccine doses are packaged and ready to ship immediately if clinical trials are successful and the Food and Drug Administration authorizes its use.
Related News Articles
Headline
The AHA’s American Organization of Nursing Leadership affiliate, the American Nurses Association, and Johnson & Johnson this week released a report…
Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
Throughout the COVID-19 pandemic, Sutter Health in Northern California used the range of its system to meet the needs of patients, staff and clinicians, from…
Headline
U.S. life expectancy fell by an average of 1.5 years in 2020 to 77.3 years, primarily due to COVID-19, the Centers for Disease Control and Prevention reported…